Reviewer	Representation	Employment	Consultant	Speakers Bureau	Ownership/ Partnership/ Principal	Personal Research	Institutional, Organizational, or Other Financial Benefit	Expert Witness
Andrew D. Krahn	AHA/ACC Atrial Fibrillation Peer Review Committee Chair	University of British Columbia	None	None	CCS* HRS*	None	None	None
Jason G. Andrade	AHA/ACC Atrial Fibrillation Peer Review Committee	University of Montreal	Biosense Webster Medtronic	Bayer Bristol Myers Squibb/Pfizer Alliance Servier	None	Medtronic†	None	None
Craig J. Beavers	AHA/ACC Atrial Fibrillation Peer Review Committee, representing ACCP	University of Kentucky College of Pharmacy	None	None	None	None	None	None
James M. Bischoff	AHA/ACC Atrial Fibrillation Peer Review Committee, Patient Representative	Superintendent, Retired	None	None	None	None	None	None
T. Jared Bunch	AHA/ACC Atrial Fibrillation Peer Review Committee, representing HRS	University of Utah School of Medicine	None	None	None	Altathera† Boehringer Ingelheim†	Abbott‡ Altathera‡ Cardiva‡ St. Jude’s Medical‡	None
Kristen Bova Campbell	AHA/ACC Atrial Fibrillation Peer Review Committee	Duke University	Wolters Kluwer	None	None	None	None	None
Lin Yee Chen	AHA/ACC Atrial Fibrillation Peer Review Committee	University of Minnesota School of Medicine	None	None	None	None	NIH†	None
Robin Dharia	AHA/ACC Atrial Fibrillation Peer Review Committee	Thomas Jefferson University	None	None	None	None	NIH†	None
Michael P. Dorsch	AHA/ACC Atrial Fibrillation Peer Review Committee, representing JCPM	University of Michigan	None	None	None	None	None	None
Edward P. Gerstenfeld	AHA/ACC Atrial Fibrillation Peer Review Committee	University of California San Francisco	Biosense Webster† Medtronic St. Jude Medical	None	None	Abbott (DSMB)† Adagio* Boston Scientific* Thermedical (DSMB)†	Boston Scientific*	None
Aubrey E. Jones	AHA/ACC Atrial Fibrillation Peer Review Committee	University of Utah College of Pharmacy	None	None	None	AHRQ† NIH-NHLBI†	None	None
Stephanie Dwyer Kaluzna	AHA/ACC Atrial Fibrillation Peer Review Committee	University of Illinois Chicago College of Pharmacy	None	None	None	None	None	None
Luke Masha	AHA/ACC Atrial Fibrillation Peer Review Committee	Oregon Health & Science University	None	None	None	None	Ancora‡ Endotronix‡	None
Isabelle Nault	AHA/ACC Atrial Fibrillation Peer Review Committee	Quebec Heart and Lung Institute	Bristol Myers Squibb Pfizer	Bayer† Biosense Webster Medtronic Servier†	None	None	None	None
Peter A. Noseworthy	AHA/ACC Atrial Fibrillation Peer Review Committee	Mayo Clinic	None	None	None	None	Anumana* Milestone£	None
Cara N. Pellegrini	AHA/ACC Atrial Fibrillation Peer Review Committee	University of California San Francisco	Abbott Biosense Webster Cook Medical Medtronic	None	None	None	None	None
Stylianos E. Tzeis	AHA/ACC Atrial Fibrillation Peer Review Committee	Mitera Hospital	Pfizer	None	None	None	Bayer‡	None
Annabelle Santos Volgman	AHA/ACC Atrial Fibrillation Peer Review Committee	Rush University Medical Center	Bristol Myers Squibb Foundation DCICDP Janssen Pharmaceuticals Merck Pfizer Sanofi Aventis†	None	None	NIH†	Apple* Novartis‡	None
Emily P. Zeitler	AHA/ACC Atrial Fibrillation Peer Review Committee	Dartmouth Hitchock Medical Center	Abbott Biosense Webster Medtronic	None	None	Boston Scientific† Sanofi Aventis*	None	None

This table represents all reviewers’ relationships with industry and other entities that were reported at the time of peer review, including those not deemed to be relevant to this document, at the time this document was under review. The table does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of $5% of the voting stock or share of the business entity, or ownership of $5,000 of the fair market value of the business entity; or if funds received by the person from the business entity exceed 5% of the person’s gross income for the previous year. Relationships that exist with no financial benefit are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Please refer to http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/relationships-with-industry-policy for definitions of disclosure categories or additional information about the ACC/AHA Disclosure Policy for Writing Committees.

^*No financial benefit.

^†Significant relationship.

^‡This disclosure was entered under the Clinical Trial Enroller category in the ACC’s disclosure system. To appear in this category, the author acknowledges that there is no direct or institutional relationship with the trial sponsor as defined in the (ACCF or AHA/ACC) Disclosure Policy for Writing Committees.

ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; AACP, American Association of Colleges of Pharmacy; AHA, American Heart Association; AHRQ, Agency for Healthcare Research and Quality; CCS, Canadian Cardiovascular Society; DCICDP, Diverse Clinical Investigator Career Development Program; DSMB; data and safety monitoring board; HRS, Heart Rhythm Society; JCPM, ACC/AHA Joint Committee on Performance Measures, NHLBI, National Heart, Lung, and Blood Institute; and NIH, National Institutes of Health.